# US 2024/0189277 A1 · Ophthalmic formulations for sustained neuroprotection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189277 A1
- Document ID: US20240189277A1
- Status: Published application
- Kind: A1
- Application number: 18/554,928
- Filed: 2022-04-14
- Published: 2024-06-13
- Earliest claimed: 2021-04-16
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Laura Ensign; Justin Hanes; Yoo Chun Kim; Tung Heng Hsueh
- Web page: https://patentgrep.com/patent/US20240189277A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Administration of therapeutic, prophylactic, or diagnostic agents that bind to a receptor or ligand in the eye or to the skin in microcrystalline form leads to increased delivery and long-lasting activity within the eye as compared with administration of the agent in non-crystalline form. Compositions and methods for delivery of active agents in microcrystalline form to the eye for the treatment, prevention and diagnosis of eye diseases and disorders are provided. In preferred embodiments, microcrystals include sunitinib malate in complex with pamoic acid. Administration of microcrystals of sunitinib malate/pamoic acid to the eye provides protection from glaucoma for up to 6 months or longer without retinal toxicity, following a single injection into the eye.

## Claims

### Claim 1

An injectable formulation for administration to the eye, comprising
(a) one or more therapeutic, prophylactic or diagnostic agents in the form of microcrystals; and
(b) one or more pharmaceutically acceptable excipients for administration into the eye.

### Claim 2 (depends on 1)

The injectable formulation of claim 1, wherein the one or more therapeutic agents, prophylactic agents, or diagnostic agents bind to a ligand or receptor in or on the eye.

### Claim 3 (depends on 2)

The injectable formulation of claim 2, wherein the one or more therapeutic agents is an inhibitor of dual leucine zipper kinase (DLK).

### Claim 4 (depends on 2)

The injectable formulation of claim 2, wherein the one or more therapeutic agents, prophylactic agents, and/or diagnostic agents bind to melanin with a dissociation constant (Kd) of less than 1×10−3 M, 1×10−4 M, 1×10−5 M, or 1×10−6 M.

### Claim 5 (depends on 2)

The injectable formulation of claim 2, wherein the one or more therapeutic agents or prophylactic agents is sunitinib, acriflavine, or derivative, analogue, or prodrug thereof.

### Claim 6 (depends on 2)

The injectable formulation of claim 2, wherein the microcrystals are formed of sunitinib and pamoic acid.

### Claim 7 (depends on 1)

The injectable formulation of claim 1, wherein the size of the microcrystals is between about 0.1 microns and about 500 microns.

### Claim 8 (depends on 1)

The injectable formulation of claim 1, wherein the formulation has a pH between 6 and 8.

### Claim 9 (depends on 1)

The injectable formulation of claim 1, formulated for intravitreal, subconjunctival, or suprachoroidal administration.

### Claim 10 (depends on 1)

The injectable formulation of claim 1, wherein the formulation does not contain a preservative or surfactant.

### Claim 11 (depends on 1)

The injectable formulation of claim 1, wherein the volume of formulation is between about 0.1 μl and about 100 μl.

### Claim 12 (depends on 1)

The injectable formulation of claim 1, wherein the one or more active agents in the microcrystals are in an amount effective to provide therapeutic or prophylactic efficacy for at least six months or longer at or around the site of application in the eye.

### Claim 13 (depends on 1)

A method for preventing and treating one or more diseases, conditions, or injuries of the eye in a subject comprising administering to the eye of the subject a therapeutically effective amount of the formulation of claim 1.

### Claim 14 (depends on 13)

The method of claim 13, wherein the one or more diseases, conditions, and injuries of the eye are diseases of the posterior segment of the eye.

### Claim 15 (depends on 13)

The method of claim 13, wherein the one or more diseases, conditions, and injuries of the eye are disease of the retina, choroid, and/or optic nerve.

### Claim 16 (depends on 13)

The method of claim 13, wherein the one or more diseases, conditions, and injuries of the eye are selected from the group consisting of retinal tear, retinal detachment, diabetic retinopathy, epiretinal membrane, macular hole, macular degeneration, retinitis pigmentosa, retinal neovascularization, and choroid neovascularization.

### Claim 17 (depends on 13)

The method of claim 13, wherein the formulation delivers an effective amount of microcrystals of therapeutic agent to the choroid and/or retinal pigmented epithelium (RPE) in the eye to reduce retinal and/or choroidal neovascularization.

### Claim 18 (depends on 17)

The method of claim 17, wherein the amount of therapeutic agent(s) administered as microcrystals is effective to reduce retinal and/or choroidal neovascularization by 10%, 20%, 30%, 40%, 50%, or more than 50% of the equivalent amount of the same active agent(s) delivered not in the form of microcrystals.

### Claim 19 (depends on 13)

The method of claim 13, wherein the formulation is administered via intravitreal, subconjunctival, or suprachoroidal injection.

### Claim 20 (depends on 13)

The method of claim 13, wherein the formulation is administered once a week or less frequently.

### Claim 21 (depends on 13)

The method of claim 13, wherein the method provides therapeutic or prophylactic efficacy in the subject following a single administration for a period of time selected from one week, two weeks, three weeks, one month, two months, three months, four months, five months, six months, eight months, ten months, and one year.

### Claim 22 (depends on 7)

The injectable formulation of claim 7 wherein the size of the microcrystals is between about 1 micron and about 250 microns.

### Claim 23 (depends on 11)

The injectable formulation of claim 11, wherein the volume of formulation is between about 1 μl and 50 μl.
